Europe is at a crossroads in advanced therapies. While it holds world-class capabilities in science, manufacturing, and regulation, fragmented policy frameworks and systemic inefficiencies threaten its ability to lead in the development and delivery of Advanced Therapy Medicinal Products (ATMPs).
In June 2025, ARM and CEOs from 30 + cell and gene therapy companies issued a joint call to EU leaders urging them that Europe must seize this once-in-a-generation opportunity to bring transformative therapies to patients. Our call to action features a policy blueprint with recommendations to make this a reality.
This blueprint sets out four priority areas for policy action based on qualitative insights from CEOs across Europe’s ATMP ecosystem. These recommendations are designed to align with the forthcoming EU Biotech Act, the European Life Science Strategy, and broader ambitions around strategic autonomy and innovation leadership. Implementing these actions will help ensure that Europe remains globally competitive, secures access for patients, and translates scientific excellence into long-term economic and health value.
